Fundamental Analysis of FIBROGEN INC(NASDAQ:FGEN) stock

Fundamental Rating

Taking everything into account, FGEN scores 2 out of 10 in our fundamental rating. FGEN was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of FGEN have multiple concerns. While showing a medium growth rate, FGEN is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year FGEN has reported negative net income.

FGEN had a negative operating cash flow in the past year.

FGEN had negative earnings in each of the past 5 years.

In the past 5 years FGEN reported 4 times negative operating cash flow.

1.2 Ratios

FGEN has a Return On Assets of -67.11%. This is in the lower half of the industry: FGEN underperforms 62.97% of its industry peers.

		Industry Rank	Sector Rank
ROA	-67.11%
ROE	N/A
ROIC	N/A

ROA(3y)-50.91%

ROA(5y)-36.92%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

FGEN's Gross Margin of 87.27% is amongst the best of the industry. FGEN outperforms 91.30% of its industry peers.

FGEN's Gross Margin has declined in the last couple of years.

FGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	87.27%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.8%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

FGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for FGEN has been increased compared to 1 year ago.

The number of shares outstanding for FGEN has been increased compared to 5 years ago.

The debt/assets ratio for FGEN is higher compared to a year ago.

2.2 Solvency

FGEN has an Altman-Z score of -7.40. This is a bad value and indicates that FGEN is not financially healthy and even has some risk of bankruptcy.

FGEN has a Altman-Z score of -7.40. This is in the lower half of the industry: FGEN underperforms 71.84% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-7.4

ROIC/WACCN/A

WACC6.36%

2.3 Liquidity

A Current Ratio of 1.52 indicates that FGEN should not have too much problems paying its short term obligations.

FGEN has a worse Current ratio (1.52) than 83.11% of its industry peers.

FGEN has a Quick Ratio of 1.33. This is a normal value and indicates that FGEN is financially healthy and should not expect problems in meeting its short term obligations.

FGEN has a worse Quick ratio (1.33) than 83.62% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.52
Quick Ratio	1.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.83% over the past year.

The Revenue has been growing slightly by 5.00% in the past year.

Measured over the past years, FGEN shows a decrease in Revenue. The Revenue has been decreasing by -7.05% on average per year.

EPS 1Y (TTM)10.83%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q18.57%

Revenue 1Y (TTM)5%

Revenue growth 3Y-5.72%

Revenue growth 5Y-7.05%

Revenue growth Q2Q-21.11%

3.2 Future

Based on estimates for the next years, FGEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.04% on average per year.

Based on estimates for the next years, FGEN will show a quite strong growth in Revenue. The Revenue will grow by 8.97% on average per year.

EPS Next Y52.89%

EPS Next 2Y35.77%

EPS Next 3Y26.87%

EPS Next 5Y15.04%

Revenue Next Year-3.45%

Revenue Next 2Y1.64%

Revenue Next 3Y7.71%

Revenue Next 5Y8.97%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FGEN. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FGEN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as FGEN's earnings are expected to grow with 26.87% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y35.77%

EPS Next 3Y26.87%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

FGEN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

FIBROGEN INC

NASDAQ:FGEN (5/2/2024, 12:33:08 PM)

1.22

+0.05 (+4.27%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap120.50M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-67.11%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	87.27%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.35

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.52
Quick Ratio	1.33
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)10.83%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y52.89%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)5%

Revenue growth 3Y-5.72%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

FIBROGEN INC (FGEN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens